Aquestive Therapeutics (NASDAQ:AQST) Rating Lowered to Hold at ValuEngine

ValuEngine cut shares of Aquestive Therapeutics (NASDAQ:AQST) from a buy rating to a hold rating in a research report report published on Tuesday morning, ValuEngine reports.

Several other analysts have also recently commented on AQST. Wedbush restated a buy rating and issued a $37.00 price target on shares of Aquestive Therapeutics in a report on Monday. Zacks Investment Research upgraded shares of Aquestive Therapeutics from a hold rating to a buy rating and set a $6.00 price objective on the stock in a report on Monday, November 11th. Finally, HC Wainwright reiterated a buy rating and set a $14.00 price objective (up from $12.00) on shares of Aquestive Therapeutics in a report on Monday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $18.40.

NASDAQ AQST opened at $8.75 on Tuesday. The business’s 50-day moving average price is $5.14 and its 200 day moving average price is $4.19. Aquestive Therapeutics has a twelve month low of $2.95 and a twelve month high of $10.00. The company has a market capitalization of $221.48 million, a PE ratio of -3.13 and a beta of 2.70.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC increased its holdings in shares of Aquestive Therapeutics by 6.8% during the 3rd quarter. Squarepoint Ops LLC now owns 40,777 shares of the company’s stock worth $130,000 after buying an additional 2,587 shares during the last quarter. California Public Employees Retirement System raised its position in shares of Aquestive Therapeutics by 5.8% in the 3rd quarter. California Public Employees Retirement System now owns 120,900 shares of the company’s stock worth $384,000 after buying an additional 6,600 shares during the period. Meeder Asset Management Inc. raised its position in shares of Aquestive Therapeutics by 460.2% in the 3rd quarter. Meeder Asset Management Inc. now owns 8,129 shares of the company’s stock worth $26,000 after buying an additional 6,678 shares during the period. Russell Investments Group Ltd. acquired a new position in Aquestive Therapeutics in the third quarter valued at $46,000. Finally, Morgan Stanley boosted its holdings in Aquestive Therapeutics by 706.1% in the second quarter. Morgan Stanley now owns 17,323 shares of the company’s stock valued at $73,000 after acquiring an additional 15,174 shares during the last quarter. 54.25% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Read More: Put Option

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.